Neurogenetics

, Volume 5, Issue 1, pp 81–82

Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma

  • Masahiro Mizoguchi
  • Catherine L. Nutt
  • David N. Louis
Letter to the Editors

Keywords

CBL-C SPRED3 Human glioblastoma 

References

  1. 1.
    Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, Louis DN (2002) Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res 62:4100–4108PubMedGoogle Scholar
  2. 2.
    Dikic I, Giordano S (2003) Negative receptor signalling. Curr Opin Cell Biol 15:128–135CrossRefPubMedGoogle Scholar
  3. 3.
    Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, Penninger J, Lipkowitz S (1999) cbl-3: a new mammalian cbl family protein. Oncogene 18:3365–3375CrossRefPubMedGoogle Scholar
  4. 4.
    Kato R, Nonami A, Taketomi T, Wakioka T, Kuroiwa A, Matsuda Y, Yoshimura A (2003) Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation. Biochem Biophys Res Commun 302:767–772CrossRefPubMedGoogle Scholar
  5. 5.
    Thien CB, Walker F, Langdon WY (2001) RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. Mol Cell 7:355–365PubMedGoogle Scholar
  6. 6.
    Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A (2001) Spred is a Sprouty-related suppressor of Ras signalling. Nature 412:647–651CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Masahiro Mizoguchi
    • 1
  • Catherine L. Nutt
    • 1
  • David N. Louis
    • 1
    • 2
  1. 1.Molecular Neuro-Oncology Laboratory and Molecular Pathology Unit, Department of Pathology, Cancer Center and Neurosurgical ServiceMassachusetts General Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Molecular Pathology Unit, 149–7151Massachusetts General Hospital—EastCharlestownUSA

Personalised recommendations